Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (BMY)
NYSE:BMY
BMY Stock Chart & Stats
$52.15
-$0.69(-1.21%)
At close: 4:00 PM EST
$52.15
-$0.69(-1.21%)
Day’s Range― - ―
52-Week Range$42.52 - $63.33
Previous CloseN/A
Volume3.98M
Average Volume (3M)15.58M
Market Cap
$106.16B
Enterprise Value$126.55B
Total Cash (Recent Filing)$16.50B
Total Debt (Recent Filing)$51.04B
Price to Earnings (P/E)17.6
Beta0.23
Next Earnings
Feb 05, 2026EPS Estimate
1.61Last Dividend Ex-Date
Oct 03, 2025Dividend Yield4.76%
Share Statistics
EPS (TTM)1.63
Shares Outstanding2,035,753,000
10 Day Avg. Volume13,963,412
30 Day Avg. Volume15,580,346
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)7.02
Price to Sales (P/S)2.37
P/FCF Ratio8.22
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue2.63
Enterprise Value/Gross Profit4.00
Enterprise Value/Ebitda8.49
Forecast
1Y Price Target
$52.33Price Target Upside0.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressThe Data Monitoring Committee recommended enrolling additional patients in Cobenfy’s ADEPT-2 trial in Alzheimer’s disease psychosis patients.
Management ConfidenceManagement has previously emphasized their confidence in the overall program in Alzheimer's Psychosis.
Product DevelopmentBMY is working to expand the label for Cobenfy across a number of additional indications, including Alzheimer's Disease Psychosis (ADP), Alzheimer's agitation, Alzheimer's cognition impairment, and bipolar depression I.
Bears Say
Clinical IrregularitiesBMY noted that following a thorough blinded review of the ADEPT-2 study data, irregularities were identified due to clinical trial execution at a small number of study sites.
Clinical Trial DelaysDelay in ADEPT-2 results confirms feelings of unease from investors heading into the year-end readout.
Trial SetbacksThe Milvexian Ph3 trial for Acute Coronary Syndrome (ACS) was unlikely to meet the primary efficacy endpoint of time to first occurrence of MACE.
Bristol-Myers Squibb News
BMY FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was $42.52 and its highest was $63.33 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Bristol-Myers Squibb’s market cap is $106.16B.
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Feb 05, 2026 which is in 61 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Oct 30, 2025. The company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.518 by $0.112.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of $0.62 which represents an annual dividend yield of 4.76%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is 1.61.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,035,753,000 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of $1.63 in its last earnings report, beating expectations of $1.518. Following the earnings report the stock price went up 7.089%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Currently, no hedge funds are holding shares in BMY
Bristol-Myers Squibb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$52.33 (0.35% Upside)
$52.33 (0.35% Upside)
Blogger Sentiment
Bullish
BMY Sentiment 90%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 2.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.96%
12-Months-Change
Fundamentals
Return on Equity
33.84%
Trailing 12-Months
Asset Growth
3.44%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Bristol-Myers Squibb (BMY) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. The company operates in various therapeutic areas, including oncology, immunology, cardiovascular, and fibrosis, with a strong portfolio of pharmaceuticals and biologics. Core products include well-known drugs such as Opdivo, Eliquis, and Revlimid. BMY is committed to advancing science through research and collaborations to address unmet medical needs.
BMY Company Deck
BMY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with strong growth in the portfolio, increased revenue guidance, and successful business development activities. However, there remain challenges with the adoption of new products like Cobenfy and the uncertainty surrounding IRA negotiations.View all BMY earnings summariesBMY Revenue Breakdown
53.29% Legacy Portfolio
46.71% Growth Portfolio
BMY Stock 12 Month Forecast
Average Price Target
$52.33
▲(0.35% Upside)
Technical Analysis
Ownership Overview
0.05% Insiders
22.33% Mutual Funds
8.12% Other Institutional Investors
41.94% Public Companies and Individual Investors